• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library

    Huahai Pharma Recieves Warning Letter

    FDA

    FDA Issues Form 483 to Zhejiang Huahai Pharmaceutical

    FDA

    Zhejiang Huahai Pharma Receives FDA Warning Letter

    FDA

    Enforcement Report - Week of February 6, 2019

    FDA

    Update on the review of CEP applications for sartans (18 Jan 2019)

    EDQM

    FDA warns API manufacturer involved in valsartan recall

    FDA

    Mylan Expands Voluntary Nationwide Recall of Valsartan Tablets Due to Trace NDEA

    FDA

    Sandoz Recalls Losartan Potassium & Hydrochlorothiazide Due to Trace NDEA

    FDA

    FDA updates on angiotensin II receptor blocker (ARB) recalls

    FDA

    FDA releases method for detection and quantification of both NDMA and NDEA

    FDA

    Health Canada finds Zhejiang Huahai Pharmaceuticals site non-compliant with GMP

    HEALTH CANADA

    Zhejiang Huahai Pharmaceutical Fails EDQM Inspection

    EDQM

    EU inspection finds Zhejiang Huahai site non-compliant for manufacture of valsartan

    EMA

    Zhejiang Huahai Pharmaceutical is on FDA Import Alert List

    FDA

    Zhejiang Huahai Pharmaceutical Receives FDA Form 483

    FDA

    Zhejiang Huahai Pharmaceutical on Health Canada Inspection List

    HEALTH CANADA

    FDA provides update on its ongoing investigation into valsartan products

    FDA

    Health Canada advises of a second impurity in recalled valsartan drugs

    HEALTH CANADA

    Health Canada updates Canadians on recalled valsartan drugs containing NDMA

    HEALTH CANADA

    Enforcement Report - Week of August 29, 2018

    FDA

    Torrent Pharma Issues Recall of Valsartan Containing Drugs-Additional Lots Added

    FDA

    Update on medicines containing valsartan from Zhejiang Tianyu

    EMA

    Torrent Pharmaceuticals Voluntarily Recalls Valsartan/Amlodipine/HCTZ Tablets

    FDA

    Zhejiang Huahai Pharmaceutical API Manufacturer Receives FDA Form 483

    FDA

    Zhejiang Huahai Pharmaceutical FDF and API Manufacturer Receives FDA Form 483

    FDA

    Enforcement Report - Week of August 1, 2018

    FDA

    EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity

    EMA

    Enforcement Report - Week of January 17, 2018

    FDA

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.